8-K: Sensei Biotherapeutics Reports Strong Solnerstotug Data

Sensei Biotherapeutics announced positive Phase 1/2 clinical results for solnerstotug in PD-(L)1 resistant tumors, showing durable progression-free survival and a favorable safety profile.

Summary

• Sensei Biotherapeutics reported new clinical results from the dose expansion portion of its Phase 1/2 trial for solnerstotug (SNS-101), a VISTA-targeting antibody.
• The trial evaluated solnerstotug as monotherapy and in combination with cemiplimab (Libtayo) in patients with hot and cold tumor types.
• In the higher 15 mg/kg dose cohort, solnerstotug combined with cemiplimab achieved a 6-month progression-free survival (PFS) of 50% in patients with PD-(L)1 resistant hot tumors (n=19).
• The overall 6-month PFS rate was 37% among 41 hot tumor patients who had previously received and progressed on PD-(L)1 therapy.
• All six observed clinical responses, including a complete response, occurred in the 15 mg/kg dose cohort, with no objective responses at the 3 mg/kg dose.
• A Merkel Cell Carcinoma patient achieved a durable complete response at week 18, lasting 54+ weeks.
• Responses were characterized by a late onset (between 18 and 54 weeks) and durable disease control, a differentiated pattern compared to typical PD-(L)1 therapies.
• The safety profile was favorable, with only six mild (Grade 1) cytokine release syndrome (CRS) events observed across all 98 Phase 1 patients, all manageable and occurring in the 15 mg/kg cohort.
• No new safety signals were identified, and the safety profile remains consistent with prior data.
• No responses were observed in 20 patients with Microsatellite Stable Colorectal (MSS CRC) cold tumors.
• The company plans to initiate two Phase 2 studies in 2026, subject to FDA feedback and sufficient capital: a randomized trial in 2nd line NSCLC and a single-arm study in PD-(L)1 resistant Merkel Cell Carcinoma.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong clinical data for solnerstotug in a challenging patient population (PD-(L)1 resistant tumors), demonstrating superior efficacy compared to historical benchmarks and a favorable safety profile. The clear plans for advancing to Phase 2 studies in commercially attractive indications further bolster positive sentiment, despite the contingency of future capital raise.

Positives

• Achieved a 6-month progression-free survival (PFS) of 50% in the 15 mg/kg dose cohort for PD-(L)1 resistant hot tumors, significantly exceeding historical benchmarks of 10-20% for standard treatments like docetaxel.
• Demonstrated dose-dependent activity, with all six clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort.
• Exhibited a favorable safety profile with only six mild (Grade 1) cytokine release syndrome (CRS) events across all patients, indicating good tolerability compared to other checkpoint inhibitor combinations.
• Observed durable disease control and a unique pattern of late-onset responses (18-54 weeks), suggesting a complementary mechanism of action to PD-(L)1 inhibitors.
• Identified a clear path forward with planned Phase 2 studies in commercially attractive indications like Non-Small Cell Lung Cancer (NSCLC) and Merkel Cell Carcinoma (MCC), with potential for accelerated approval in MCC.

Negatives

• No objective responses were observed in the 3 mg/kg dose cohort, indicating a clear dose-response relationship where lower doses may not be effective.
• No signal of activity or responses were observed in patients with Microsatellite Stable Colorectal (MSS CRC) cold tumors (n=20), suggesting limited efficacy in this patient population.
• The initiation of Phase 2 studies is subject to the company's ability to raise sufficient capital, which introduces a financing contingency.

Risks

• Uncertainties inherent in the development of therapeutic product candidates, including the risk that solnerstotug may not be successfully developed or commercialized.
• Risk of delay or cessation of any planned clinical trials of solnerstotug.
• Risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical studies and clinical trials, will not be replicated or will not continue in ongoing or future studies.
• Risk that solnerstotug will not have the safety or efficacy profile that Sensei anticipates.
• Risks associated with dependence on third-party suppliers and manufacturers, including sole source suppliers.
• Risks regarding the accuracy of estimates of expenses, capital requirements, and needs for additional financing.
• The planning and initiation of Phase 2 studies are subject to FDA feedback and the company's ability to raise sufficient capital.

Future Outlook

Sensei Biotherapeutics plans to advance solnerstotug into two Phase 2 studies starting in 2026. One will be a randomized trial in 2nd line Non-Small Cell Lung Cancer (NSCLC) for patients who have failed anti-PD-(L)1 treatment, comparing solnerstotug plus a PD-(L)1 inhibitor against chemotherapy. The second will be a single-arm study in PD-(L)1 resistant Merkel Cell Carcinoma (MCC) patients, aiming for potential accelerated approval. These plans are contingent on FDA feedback and the company's ability to raise sufficient capital.

Management Comments

• Ron Weitzman, M.D., Chief Medical Officer: "Solnerstotugs emerging dose-dependent activity in refractory hot tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies... The data suggest that selective blockade of VISTA within the tumor microenvironment may help re-engage exhausted T cells, even after PD-1 failure, a goal long considered out of reach."
• Kyriakos Papadopoulos, M.D., Co-Director of Clinical Research at START, San Antonio: "This pattern of delayed, durable responses is unusual among immunotherapies... It may indicate that solnerstotug acts through a mechanism that is complementary to PD-(L)1 in resistant tumors."
• John Celebi, President and Chief Executive Officer: "Were pleased by the emerging signs of dose-related activity, durability, and a favorable safety profilekey characteristics of a potentially differentiated immunotherapy... These results provide a foundation for our planned Phase 2 development program as we work to better define solnerstotugs role in treating challenging patient populations."

Industry Context

The results for solnerstotug are significant in the oncology industry, particularly for patients with PD-(L)1 resistant tumors, a population with high unmet medical need and limited treatment options. Resistance to immune checkpoint blockade is a major challenge, and the observed 50% 6-month PFS in this refractory setting, coupled with a favorable safety profile, positions solnerstotug as a potentially differentiated immunotherapy. The unique late-onset, durable response pattern suggests a novel mechanism of action that could be complementary to existing PD-(L)1 therapies, offering a new therapeutic avenue where current options are often limited to chemotherapy or palliative care.

Comparison to Industry Standards

• Solnerstotug (15 mg/kg) + cemiplimab achieved a 6-month PFS of 50% in PD-(L)1-refractory hot tumors, which compares favorably to docetaxel, a widely used chemotherapy in 2nd line post-PD-(L)1 NSCLC, which typically has a 6-month PFS of 10-20%.
• Compared to other immune checkpoint inhibitor combinations in PD-1-refractory melanoma, solnerstotug's 50% 6-month PFS surpasses the 34% seen with Ipilimumab + Nivolumab (which also had high toxicity and a 40% discontinuation rate) and the 29% seen with Relatlimab + Nivolumab (which was well tolerated).
• The favorable safety profile of solnerstotug, with only mild (Grade 1) CRS events, compares positively to the high toxicity profiles observed with some other combination immunotherapies, such as Ipilimumab + Nivolumab.
• The observed late-onset, durable responses (18-54 weeks) are unusual for immunotherapies, which typically show a time to response of 2-3 months, suggesting a differentiated mechanism of activity compared to standard PD-(L)1 therapies.

Stakeholder Impact

• **Shareholders:** Positive impact due to promising clinical data for the lead product candidate, potentially increasing company valuation and future revenue prospects. However, the need for future capital raises could lead to dilution.
• **Patients:** Significant positive impact, especially for those with PD-(L)1 resistant tumors who currently have limited effective treatment options. Solnerstotug offers a new, potentially more effective and tolerable therapeutic avenue.
• **Healthcare Providers:** Provides a new, potentially effective treatment option for a difficult-to-treat patient population, expanding the therapeutic arsenal against advanced cancers.
• **Regulatory Authorities:** The positive data and planned Phase 2 studies will be of interest to the FDA, particularly the potential for accelerated approval in Merkel Cell Carcinoma, addressing an unmet medical need.

Next Steps

• Host an investor webcast on October 20, 2025, to discuss the clinical trial results.
• Update the corporate presentation on the company's website.
• Plan two Phase 2 studies to begin in 2026, subject to FDA feedback and the ability to raise sufficient capital.
• Initiate a randomized Phase 2 trial in 2nd line NSCLC for patients who have received and failed anti-PD-(L)1 treatment.
• Initiate a single-arm Phase 2 study in PD-(L)1 resistant Merkel Cell Carcinoma patients, with potential for accelerated approval.

Key Dates

Recommendation

The strong clinical data for solnerstotug, particularly the 50% 6-month PFS in PD-(L)1 resistant hot tumors, significantly outperforms historical benchmarks in a high unmet need area. The favorable safety profile and the unique, durable late-onset responses suggest a differentiated and potentially highly valuable therapeutic mechanism. The clear strategic path to Phase 2 studies in commercially attractive indications, with potential for accelerated approval, indicates strong future growth potential. While the need for future capital raises introduces some risk, the compelling efficacy and safety profile make Sensei Biotherapeutics an attractive investment for long-term growth in the oncology space.

Keywords

Solnerstotug, VISTA, Immunotherapy, Oncology, PD-1 resistant, Cancer treatment, Clinical trial, Phase 1/2, Biotechnology, Non-Small Cell Lung Cancer, Merkel Cell Carcinoma, Progression-Free Survival, V-domain Ig suppressor of T cell activation, TMAb platform